EUVIMEDEUVIMED entdecken
Crossref

Prospective multicenter evaluation of the ARCHIMEDES biodegradable pancreatic stent for the prevention of post-ERCP pancreatitis

G Marcellier, M Giovannini, P Rivallin, J P Ratone, S Hoibian, Y Dahel, B Jais, K Berri, A Solovyev, F Prat, F Caillol

Endoscopy · 01.06.2026 · 58 (S 03 S 03) · S61

DOI: 10.1055/s-0046-1820737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von G Marcellier und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Post-ERCP pancreatitis is the most frequent complication of ERCP. Two preventive measures are currently recommended: rectal indomethacin for all patients and temporary pancreatic stenting for those at high risk. However, stents may cause ductal injury, require follow-up imaging, and often need a second endoscopy for removal. A biodegradable stent could provide the same preventive benefit while avoiding these drawbacks. The ARCHIMEDES biodegradable pancreatic stent has demonstrated encouraging feasibility and safety results in preliminary studies. We conducted a prospective multicenter study to assess the safety, efficacy, and spontaneous clearance of this stent for the prevention of post-ERCP pancreatitis.

Methods

A polymer resorbable stent (Archimedes, Q3 Medical, USA) with fast resorption (12 days) was positioned under endoscopic and fluoroscopic control during high-risk ERCP defined following ESGE guidelines (Endoscopic papillectomy, known or suspected sphincter of Oddi dysfunction, pancreatic sphincterotomy, precut sphincterotomy, pancreatic guidewire–assisted biliary cannulation, and papillar dilation) or the combination of 2 among 3 risk factors (Women gender, Thin biliary duct, history of pancreatitis). Patients signed informed consent. The main outcome was clearance of the stent at D-30 after ERCP. Secondary outcomes included side effects (Pancreatitis among others, graded regarding AGREE classification) and the ability to technically insert the stent during the procedure. The study was single armed, multicenter (Paoli Calmette Institute, Marseille & France Beaujon Hospital, Clichy, France). We planned to include 46 patients in the study with 45 days of follow-up.

Results

A total of 52 patients were included in the study. The median age was 65 years (IQR 20–93), and 55.8% were male while 44.2% were female. Indications for pancreatic prophylactic stenting were the following: 22 patients underwent endoscopic papillectomy, 3 had sphincter of Oddi dysfunction, 18 underwent pancreatic sphincterotomy, 3 required an endoscopic precut, 1 underwent papillary dilation, 19 required double-guidewire technique for difficult biliary canulation, 11 had a narrow biliary duct, and 9 had a history of pancreatitis. Regarding the primary outcome, 3 patients (5.8%) still had residual stent fragments at day 30. None developed pancreatitis, and the stents fully resorbed during follow-up. Technical success for stent insertion was 100%. Regarding ERCP-related complications, 4 patients (7.7%) developed acute pancreatitis (mild to moderate, AGREE≤2), 8 experienced bleeding (15%) (AGREE=3), 1 had a perforation (1.9%), and 1 developed cholangitis (1.9%); the latter two were also classified as severe (AGREE=3).

Conclusions

This is the first prospective study evaluating the benefit of Archimedes biodegradable stents in preventing acute pancreatitis during high-risk endoscopic procedures. No patient required subsequent endoscopy for stent removal. Because the study was single armed and involved high-risk interventions, analyzing complication rates is challenging; however, fewer than 8% of patients developed pancreatitis, none of them being severe. These findings are encouraging regarding the safety profile of Archimedes stents and support their potential use for preventing post-ERCP pancreatitis. Publication History Article published online: 05 June 2026 © 2026. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Marcellier, G., Giovannini, M., Rivallin, P., Ratone, J. P., Hoibian, S., Dahel, Y., Jais, B., Berri, K., Solovyev, A., Prat, F., & Caillol, F. (2026). Prospective multicenter evaluation of the ARCHIMEDES biodegradable pancreatic stent for the prevention of post-ERCP pancreatitis. Endoscopy, 58(S 03 S 03), S61. https://doi.org/10.1055/s-0046-1820737

Vancouver

Marcellier G, Giovannini M, Rivallin P, Ratone JP, Hoibian S, Dahel Y, et al. Prospective multicenter evaluation of the ARCHIMEDES biodegradable pancreatic stent for the prevention of post-ERCP pancreatitis. Endoscopy. 2026;58(S 03 S 03):S61. doi:10.1055/s-0046-1820737

BibTeX
@article{Marcellier2026,
  author = {Marcellier, G and Giovannini, M and Rivallin, P and Ratone, J P and Hoibian, S and Dahel, Y and Jais, B and Berri, K and Solovyev, A and Prat, F and Caillol, F},
  title = {Prospective multicenter evaluation of the ARCHIMEDES biodegradable pancreatic stent for the prevention of post-ERCP pancreatitis},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {S 03 S 03},
  pages = {S61},
  doi = {10.1055/s-0046-1820737}
}
Kostenlos starten →